Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

iControl Chronic Kidney Disease (iControl CKD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03951363
Recruitment Status : Suspended (Suspended due to COVID-19 restrictions (funding and in-person visits))
First Posted : May 15, 2019
Last Update Posted : May 11, 2020
Sponsor:
Information provided by (Responsible Party):
Duke University

Brief Summary:

The proposed study is responsive to the call for obtaining enhanced preliminary data for an external grant resubmission. The goal is to demonstrate a novel approach using digital health tools to help preserve kidney function. The investigators aim to adapt a previous behavioral intervention and conduct formative testing among patients with CKD. Specifically, the investigators will:

Aim 1: Modify an existing technology platform to build the iControl CKD system and adapt intervention content to reflect behavioral guidelines for patients with mild to moderate CKD.

Aim 2: Conduct qualitative interviews and user testing among patients with CKD to obtain feedback on the design of the intervention.

Aim 3: Conduct a prospective cohort feasibility trial to assess the feasibility and initial acceptability of the iControl CKD intervention.


Condition or disease Intervention/treatment Phase
Chronic Kidney Diseases Behavioral: interactive Obesity Treatment Approach (iOTA) Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Using Digital Health to Improve Diet and Exercise Adherence for Chronic Kidney Disease Management
Actual Study Start Date : May 13, 2019
Estimated Primary Completion Date : May 31, 2022
Estimated Study Completion Date : May 31, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Diseases

Arm Intervention/treatment
No Intervention: Qualitative Interview
Interviews: The investigators will enroll at least 10 adults 18 years or older with CKD (self-report).
Pilot Testing
Pilot Study: The investigators will enroll 30 adults at least 18 years old with mild to moderate CKD (documented estimated glomerular filtration rate (eGFR) ≥60 ml/min/1.73m2 plus albuminuria or eGFR 45-59 ml/min/1.73m2) who also have diabetes and/or hypertension.
Behavioral: interactive Obesity Treatment Approach (iOTA)
The investigators will adapt an evidence-based digital health intervention to promote adherence to nationally recommended diet and physical activity guidelines for patients with chronic kidney disease. The intervention includes goal assignment, goal tracking, and skills training messages.




Primary Outcome Measures :
  1. Proportion of participants responding to Interactive Voice Response (IVR) calls or text tracking prompts [ Time Frame: Approximately 1 Month ]
    Engagement with the intervention will be measured by calculating the proportion of participants responding to IVR calls or text tracking prompts over 1 month


Secondary Outcome Measures :
  1. Change in CKD diet adherence as measured through consumption of CKD-specific nutrients (i.e. sodium, protein, potassium, and phosphorus) [ Time Frame: Approximately 1 Month ]
    Analysis of 24-hour dietary recalls (1 weekday and 1 weekend day) at the beginning and end of the 1 month period

  2. Change in physical activity minutes [ Time Frame: Approximately 1 month ]
    Self-reported physical activity will be measured via the Paffenbarger Exercise Habits Questionnaire pre- and post intervention



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria:

Qualitative interview:

  • Age 18 or older
  • Diagnosed with CKD (self-report)
  • Proficient in English

Inclusion criteria:

Pilot Groups:

  • Age 18 or older
  • Diagnosed with mild to moderate CKD (documented eGFR ≥60 ml/min/1.73m2 plus albuminuria or eGFR 45-59 ml/min/1.73m2 )
  • Diagnosed with diabetes and/or hypertension
  • Proficient in English
  • Access to a test-enabled mobile phone
  • Willing to receive and send multiple text messages in a week

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03951363


Locations
Layout table for location information
United States, North Carolina
Duke Global Digital Health Science Center
Durham, North Carolina, United States, 27708
Sponsors and Collaborators
Duke University
Investigators
Layout table for investigator information
Principal Investigator: Dori Steinberg, PhD, RD Duke University
Layout table for additonal information
Responsible Party: Duke University
ClinicalTrials.gov Identifier: NCT03951363    
Other Study ID Numbers: Pro00101993
First Posted: May 15, 2019    Key Record Dates
Last Update Posted: May 11, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Renal Insufficiency, Chronic
Urologic Diseases
Renal Insufficiency